

Lisa Moris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3892016/publications.pdf>

Version: 2024-02-01

42
papers

3,345
citations

471509

17
h-index

276875

41
g-index

43
all docs

43
docs citations

43
times ranked

3211
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 674-689.	3.1	21
2	Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non-nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review. <i>European Urology Focus</i> , 2022, 8, 690-700.	3.1	10
3	Small-molecule profiling for steroid receptor activity using a universal steroid receptor reporter assay. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2022, 217, 106043.	2.5	3
4	Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 527-541.	3.4	3
5	Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. <i>European Urology</i> , 2022, 81, 503-514.	1.9	13
6	Diagnostic and prognostic factors in patients with prostate cancer: a systematic review. <i>BMJ Open</i> , 2022, 12, e058267.	1.9	4
7	Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy. <i>European Urology</i> , 2022, 81, 337-346.	1.9	33
8	Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100543.	3.0	7
9	Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by 68Ga-PSMA-11 PET/CT or 11C-Choline PET/CT: impact of postoperative treatments. <i>World Journal of Urology</i> , 2021, 39, 399-406.	2.2	4
10	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. <i>European Urology</i> , 2021, 79, 243-262.	1.9	1,545
11	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. <i>European Urology</i> , 2021, 79, 263-282.	1.9	633
12	Current and emerging therapies for localized high-risk prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 267-282.	2.4	3
13	A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer. <i>European Urology</i> , 2021, 80, 531-545.	1.9	21
14	A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research. <i>European Urology Oncology</i> , 2021, 4, 405-423.	5.4	26
15	Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 739-762.	3.8	38
16	The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 943-946.	3.1	6
17	The androgen receptor depends on ligand-binding domain dimerization for transcriptional activation. <i>EMBO Reports</i> , 2021, 22, e52764.	4.5	20
18	Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. <i>European Urology Focus</i> , 2020, 6, 231-234.	3.1	131

#	ARTICLE	IF	CITATIONS
19	Reply to Francesco Montorsi, Andrea Salonia, and Alberto Briganti's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. <i>Eur Urol</i> 2020;77:614-27. <i>European Urology</i> , 2020, 78, e193-e194.	1.9	1
20	Reply to Fabiana Gregucci, Roberta Carbonara, and Alba Fiorentino's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. <i>Eur Urol</i> 2020;77:614-27. <i>European Urology</i> , 2020, 78, e116-e117.	1.9	0
21	Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer. <i>Cells</i> , 2020, 9, 2494.	4.1	13
22	Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luo's Letter to the Editor re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. <i>Eur Urol</i> 2020;77:614-27. <i>European Urology</i> , 2020, 78, e120-e121.	1.9	2
23	Preoperative Risk-Stratification of High-Risk Prostate Cancer: A Multicenter Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 246.	2.8	11
24	Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. <i>European Urology</i> , 2020, 77, 614-627.	1.9	101
25	The Cancer of the Bladder Risk Assessment (COBRA) score for estimating cancer-specific survival after radical cystectomy: external validation in a large bi-institutional cohort. <i>BJU International</i> , 2020, 126, 704-714.	2.5	7
26	Comparison of postoperative complications of ileal conduits versus orthotopic neobladders. <i>Translational Andrology and Urology</i> , 2020, 9, 2541-2554.	1.4	15
27	Prognostic score predicts overall survival following complete urinary tract extirpation. <i>Scandinavian Journal of Urology</i> , 2020, 54, 70-79.	1.0	2
28	Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery. <i>European Urology Oncology</i> , 2019, 2, 589-596.	5.4	19
29	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). <i>European Urology</i> , 2019, 76, 790-813.	1.9	151
30	Comparison of Peri-operative and Early Oncological Outcomes of Robot-Assisted vs. Open Salvage Lymph Node Dissection in Recurrent Prostate Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 781.	2.8	7
31	Drivers of AR indifferent anti-androgen resistance in prostate cancer cells. <i>Scientific Reports</i> , 2019, 9, 13786.	3.3	44
32	Metastasectomy for visceral and skeletal oligorecurrent prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 1543-1549.	2.2	19
33	Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review. <i>European Urology Oncology</i> , 2019, 2, 174-188.	5.4	58
34	Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer. <i>European Urology</i> , 2019, 75, 699-702.	1.9	8
35	Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2019, 75, 967-987.	1.9	278
36	Impact of neoadjuvant chemotherapy on short-term complications and survival following radical cystectomy. <i>World Journal of Urology</i> , 2019, 37, 1857-1866.	2.2	23

#	ARTICLE	IF	CITATIONS
37	Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial. <i>BMC Cancer</i> , 2018, 18, 354.	2.6	16
38	The influence of steroid metabolism on CYP17A1 inhibitor activity. <i>Nature Reviews Urology</i> , 2017, 14, 590-592.	3.8	3
39	Tumor Volume and Clinical Failure in High-Risk Prostate Cancer Patients Treated With Radical Prostatectomy. <i>Prostate</i> , 2017, 77, 3-9.	2.3	8
40	Comparison of Functional Outcome after Extended versus Super-Extended Pelvic Lymph Node Dissection during Radical Prostatectomy in High-Risk Localized Prostate Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 280.	2.8	9
41	The N-shaped orthotopic ileal neobladder: functional outcomes and complication rates in 119 patients. <i>SpringerPlus</i> , 2016, 5, 646.	1.2	10
42	Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection. <i>Frontiers in Surgery</i> , 2016, 3, 65.	1.4	19